One Universal Common Endpoint in Mouse Models of Amyotrophic Lateral Sclerosis
Open Access
- 8 June 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20582
Abstract
There is no consensus among research laboratories around the world on the criteria that define endpoint in studies involving rodent models of amyotrophic lateral sclerosis (ALS). Data from 4 nutrition intervention studies using 162 G93A mice, a model of ALS, were analyzed to determine if differences exist between the following endpoint criteria: CS 4 (functional paralysis of both hindlimbs), CS 4+ (CS 4 in addition to the earliest age of body weight loss, body condition deterioration or righting reflex), and CS 5 (CS 4 plus righting reflex >20 s). The age (d; mean ± SD) at which mice reached endpoint was recorded as the unit of measurement. Mice reached CS 4 at 123.9±10.3 d, CS 4+ at 126.6±9.8 d and CS 5 at 127.6±9.8 d, all significantly different from each other (P<0.001). There was a significant positive correlation between CS 4 and CS 5 (r = 0.95, P<0.001), CS 4 and CS 4+ (r = 0.96, P<0.001), and CS 4+ and CS 5 (r = 0.98, P<0.001), with the Bland-Altman plot showing an acceptable bias between all endpoints. Logrank tests showed that mice reached CS 4 24% and 34% faster than CS 4+ (P = 0.046) and CS 5 (P = 0.006), respectively. Adopting CS 4 as endpoint would spare a mouse an average of 4 days (P<0.001) from further neuromuscular disability and poor quality of life compared to CS 5. Alternatively, CS 5 provides information regarding proprioception and severe motor neuron death, both could be important parameters in establishing the efficacy of specific treatments. Converging ethics and discovery, would adopting CS 4 as endpoint compromise the acquisition of insight about the effects of interventions in animal models of ALS?Keywords
This publication has 118 references indexed in Scilit:
- Lead exposure stimulates VEGF expression in the spinal cord and extends survival in a mouse model of ALSNeurobiology of Disease, 2010
- Motor neuronal protection by l-arginine prolongs survival of mutant SOD1 (G93A) ALS miceBiochemical and Biophysical Research Communications, 2009
- Decline in Daily Running Distance Presages Disease Onset in a Mouse Model of ALSNeuroMolecular Medicine, 2009
- Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant miceAmyotrophic Lateral Sclerosis, 2009
- Sensory involvement in the SOD1-G93A mouse model of amyotrophic lateral sclerosisExperimental & Molecular Medicine, 2009
- Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosisBrain, 2008
- Antioxidant strategies based on tomato-enriched food or pyruvate do not affect disease onset and survival in an animal model of amyotrophic lateral sclerosisBrain Research, 2007
- Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse modelNeuroscience Letters, 2007
- The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJournal of Neurochemistry, 2007
- Oral Administration of Memantine Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral SclerosisJournal of Clinical Neurology, 2007